Drug Type Small molecule drug |
Synonyms ZITUVIMET, ZITUVIMET XR |
Target |
Mechanism DPP-4 inhibitors(Dipeptidyl peptidase IV inhibitors), PRKAB1 activators(Protein kinase AMP-activated non-catalytic subunit beta 1 activators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date US (03 Nov 2023), |
Regulation- |
Molecular FormulaC16H15F6N5O |
InChIKeyMFFMDFFZMYYVKS-SECBINFHSA-N |
CAS Registry- |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Diabetes Mellitus, Type 2 | US | 03 Nov 2023 |